First Analysis upgraded shares of Repligen Corporation (NASDAQ:RGEN) from an equal weight rating to an overweight rating in a research note published on Monday morning, Marketbeat.com reports. They currently have $47.00 target price on the biotechnology company’s stock.

Several other research analysts have also weighed in on the company. Jefferies Group LLC reaffirmed a hold rating and issued a $40.00 target price on shares of Repligen Corporation in a research report on Thursday, September 14th. Janney Montgomery Scott increased their target price on Repligen Corporation from $42.00 to $47.00 in a research report on Friday, June 23rd. BidaskClub raised Repligen Corporation from a buy rating to a strong-buy rating in a research report on Saturday, June 24th. William Blair initiated coverage on Repligen Corporation in a research report on Friday, July 21st. They issued an outperform rating on the stock. Finally, Zacks Investment Research lowered Repligen Corporation from a buy rating to a hold rating in a research report on Friday, August 18th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $45.40.

Shares of Repligen Corporation (NASDAQ RGEN) opened at 38.27 on Monday. The company has a 50 day moving average price of $41.79 and a 200 day moving average price of $39.54. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81. The stock has a market cap of $1.43 billion, a P/E ratio of 74.89 and a beta of 1.18.

Repligen Corporation (NASDAQ:RGEN) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.05. The business had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The business’s quarterly revenue was up 11.0% on a year-over-year basis. During the same period last year, the company posted $0.16 EPS. Analysts anticipate that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/05/repligen-corporation-rgen-raised-to-overweight-at-first-analysis.html.

Large investors have recently added to or reduced their stakes in the business. Eaton Vance Management purchased a new position in Repligen Corporation in the second quarter valued at about $529,000. Benin Management CORP purchased a new position in Repligen Corporation in the second quarter valued at about $207,000. Jennison Associates LLC purchased a new position in Repligen Corporation in the second quarter valued at about $291,000. Legal & General Group Plc raised its position in Repligen Corporation by 15.3% in the second quarter. Legal & General Group Plc now owns 68,677 shares of the biotechnology company’s stock valued at $2,845,000 after purchasing an additional 9,121 shares during the period. Finally, Karp Capital Management Corp purchased a new position in Repligen Corporation in the first quarter valued at about $506,000. 97.91% of the stock is currently owned by institutional investors.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.